Connect with us


GSK, Lilly and Vir Biotechnology achieve positive results in Phase II COVID-19 study

GSK, Lilly, and Vir Biotechnology have recently presented the results of a COVID-19 study. The two monoclonal antibodies in combination have demonstrated a 70% relative reduction in the persistence of a high viral load at seven days of treatment compared to placebo. VIR-7831 is an experimental compound not approved by the FDA or any health authority.



GlaxoSmithKline (GSK), Lilly, and Vir Biotechnology make progress against COVID-19. The three companies have announced positive initial results from the Phase II BLAZE-4 study evaluating the combination of balanivimab with VIR-7831 in low-risk adults with coronavirus. 

Find more details about the latest COVID-19 study conducted by GSK, Lilly, and Vir Biotechnology with our companion app. The Born2Invest mobile app brings you the most important breakthroughs in the biotech sector and the latest finance news so you can stay informed.

What did the results reveal

The results indicated that the two monoclonal antibodies in combination have demonstrated a 70% relative reduction in persistently high viral load at seven days of treatment compared to placebo. In addition, bamlanivimad administered with VIR-7831 has demonstrated a statistically significant reduction in secondary endpoints compared to placebo. Bamlanivimab and VIR-7831 bind to different parts of the SARS-Cov-2 spyke protein. Preclinical data suggest that co-administration of these two investigational antibodies may provide protection against the current variants, which are resistant to bamlanivimab.  

“These virological data support our belief that together, bamlanivimab and VIR-7831 could be a promising option for the treatment of Covid-19,” as explained by Daniel Skovronsky, CEO and chairman of Lilly. George Scangos, CEO of Vir, commented that “this virological evaluation of two antibodies with different resistance profiles is an encouraging development in our fight against the pandemic.” 

Vir expects to continue discussions with the U.S. Food and Drug Administration (FDA) about VIR-7831 as monotherapy and co-administered with bamlanivimab. Finally, Hal Barron, CEO and president of GSK, said that these results “support our hypothesis that, by binding to a highly conserved epitope, VIR-7831 can help deliver benefits to patients.”  

VIR-7831 is not yet approved by any health authority 

VIR-7831 is an experimental compound not approved by the FDA or any health authority. The pharmaceutical consortium has applied to the FDA for emergency use authorization for VIR-7831 based on the results of the Phase III Comet-Ice study. The study has demonstrated an 85% reduction in hospitalization or death in patients who received VIR-7831 as monotherapy compared to placebo, the primary endpoint of the trial. GSK and Vir will continue discussions with the European Medicines Agency (EMA) and other regulators with the goal of making VIR-7831 available to Covid-19 patients as soon as possible.


(Featured image by Polina Tankilevitch via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.